DEEP EXPERIENCE. SHARED COMMITMENT.
"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
21
active portfolio companies
+
2000
employees worldwide
7
AP-II Investments to Date
9
successful exits
news
Jan 16, 2025
GT Medical Technologies Raises $37 Million in Series D to Advance the Expansion of GammaTile® in the U.S. for Patients with Operable Brain Tumors
GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, announced the company has completed a $37 million first close of a Series D financing round led by Evidity Health Capital and new investor Accelmed Partners
Oct 01, 2024
Accelmed Announces the Acquisition of Bioventus' Advanced Rehabilitation BusinessAccelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies, has announced that they have signed a definitive agreement to acquire Bioness Inc., the Advanced Rehabilitation subsidiary of Bioventus Inc. (Nasdaq: BVS)
Aug 19, 2024
Minerva Surgical Appoints Darin Hammers as Chief Executive Officer and Member of the Board of DirectorsMinerva Surgical announced the appointment of Darin Hammers as the new President and Chief Executive Officer and Member of the Board.
Jul 23, 2024
Bausch + Lomb Acquires Diagnostic Company Trukera MedicalBausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Trukera Medical, from its private equity owner, Accelmed Partners, and other shareholders. The tuck-in acquisition will help expand Bausch + Lomb’s surgical presence in the United States and contribute to its leading position in dry eye.
Contact Us